Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer’s Disease

Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline

(2013) Parminder Raina et al.   ANNALS OF INTERNAL MEDICINE

Current Pharmacologic Treatment of Dementia: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians

(2013) Amir Qaseem   ANNALS OF INTERNAL MEDICINE

Population Pharmacokinetic Study of Memantine: Effects of Clinical and Genetic Factors

(2013) Muriel Noetzli et al.   CLINICAL PHARMACOKINETICS

Discontinuing Donepezil or Starting Memantine for Alzheimer's Disease

(2012) Lon S. Schneider   NEW ENGLAND JOURNAL OF MEDICINE

Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease

(2012) Robert Howard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Paraoxonase 1 Gene Polymorphisms Do Not Influence the Response to Treatment in Alzheimer’s Disease

(2011) A. Klimkowicz-Mrowiec et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

BCHE and CYP2D6 genetic variation in Alzheimer’s disease patients treated with cholinesterase inhibitors

(2011) Caterina Chianella et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Role of organic cation transporters in drug-induced toxicity

(2011) Giuliano Ciarimboli   Expert Opinion on Drug Metabolism & Toxicology

Genetics of Alzheimer's Disease: An Insight Into Presenilins and Apolipoprotein E Instigated Neurodegeneration

(2011) M. Obulesu et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Active Site Gating and Substrate Specificity of Butyrylcholinesterase and Acetylcholinesterase: Insights from Molecular Dynamics Simulations

(2011) Lei Fang et al.   JOURNAL OF PHYSICAL CHEMISTRY B

Apolipoprotein E in Alzheimer's disease and other neurological disorders

(2011) Philip B Verghese et al.   LANCET NEUROLOGY

Epidemiology of Alzheimer disease

(2011) Christiane Reitz et al.   Nature Reviews Neurology

Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease

(2010) N. R. Cutler et al.   ACTA NEUROLOGICA SCANDINAVICA

Do CYP3A and ABCB1 genotypes influence the plasma concentration and clinical outcome of donepezil treatment?

(2010) Laura Magliulo et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Current status on Alzheimer disease molecular genetics: from past, to present, to future

(2010) K. Bettens et al.   HUMAN MOLECULAR GENETICS

Neurochemical basis for symptomatic treatment of Alzheimer's disease

(2010) Paul T. Francis et al.   NEUROPHARMACOLOGY

Very important pharmacogene summary

(2010) Laura M. Hodges et al.   Pharmacogenetics and Genomics

The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects

(2010) Kristel Sleegers et al.   TRENDS IN GENETICS

Identification of polymorphisms in the 3′-untranslated region of the human pregnane X receptor (PXR) gene associated with variability in cytochrome P450 3A (CYP3A) metabolism

(2010) L. Oleson et al.   XENOBIOTICA

Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance

(2009) Shu-Feng Zhou   CLINICAL PHARMACOKINETICS

A 25-week, open-label trial investigating rivastigmine transdermal patches with concomitant memantine in mild-to-moderate Alzheimer’s disease: a post hoc analysis

(2009) Martin R. Farlow et al.   CURRENT MEDICAL RESEARCH AND OPINION

Memantine in Moderately-Severe-to-Severe Alzheimerʼs Disease

(2009) Francesca Clerici et al.   DRUGS & AGING

Changes in cognitive functions of patients with dementia of the Alzheimer type following long-term administration of donepezil hydrochloride: Relating to changes attributable to differences in apolipoprotein E phenotype

(2009) Kiyoshi Kanaya et al.   Geriatrics & Gerontology International

Similar Rivastigmine Pharmacokinetics and Pharmacodynamics in Japanese and White Healthy Participants Following the Application of Novel Rivastigmine Patch

(2009) Gilbert Lefèvre et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease

(2009) O L Lopez et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Effect of a CYP2D6 polymorphism on the efficacy of donepezil in patients with Alzheimer disease

(2009) A. Pilotto et al.   NEUROLOGY

The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

(2009) Beatrice Oneda et al.   Pharmacogenetics and Genomics

Long-term Course and Effectiveness of Combination Therapy in Alzheimer Disease

(2008) Alireza Atri et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

Variability of AChE, BChE, and ChAT genes in the late-onset form of Alzheimer's disease and relationships with response to treatment with Donepezil and Rivastigmine

(2008) Renato Scacchi et al.   AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS

Association of a Single‐Nucleotide Polymorphism in the Pregnane X Receptor (PXR63396C→T) with Reduced Concentrations of Unboosted Atazanavir

(2008) Marco Siccardi et al.   CLINICAL INFECTIOUS DISEASES

Pharmacokinetics of single-dose and multiple-dose memantine in healthy chinese volunteers using an analytic method of liquid chromatography-tandem mass spectrometry

(2008) Ming-Yan Liu et al.   CLINICAL THERAPEUTICS

Interactions between the amyloid and cholinergic mechanisms in Alzheimer's disease

(2008) M PAKASKI et al.   NEUROCHEMISTRY INTERNATIONAL